Cargando…
OC.14.2 LACK OF SEROCONVERSION FOLLOWING COVID-19 VACCINATION, BUT NOT TREATMENT, IS AN INDEPENDENT RISK FACTOR FOR BREAKTHROUGH SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IGIBD STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033231/ http://dx.doi.org/10.1016/S1590-8658(23)00321-3 |
| _version_ | 1784910964445937664 |
|---|---|
| author | Macaluso, F.S. Principi, M. Facciotti, F. Contaldo, A. Todeschini, A. Saibeni, S. Bezzio, C. Castiglione, F. Nardone, O. Spagnuolo, R. Fantini, M. Riguccio, G. Conforti, F. Caprioli, F. Vigano, C. Felice, C. Fiorino, G. Correale, C. Bodini, G. Milla, M. Scardino, G. Vernero, M. Desideri, F. Bossa, F. Guerra, M. Ventimiglia, M. Mannino, M. Rizzo, G. Orlando, A. |
| author_facet | Macaluso, F.S. Principi, M. Facciotti, F. Contaldo, A. Todeschini, A. Saibeni, S. Bezzio, C. Castiglione, F. Nardone, O. Spagnuolo, R. Fantini, M. Riguccio, G. Conforti, F. Caprioli, F. Vigano, C. Felice, C. Fiorino, G. Correale, C. Bodini, G. Milla, M. Scardino, G. Vernero, M. Desideri, F. Bossa, F. Guerra, M. Ventimiglia, M. Mannino, M. Rizzo, G. Orlando, A. |
| author_sort | Macaluso, F.S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10033231 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100332312023-03-23 OC.14.2 LACK OF SEROCONVERSION FOLLOWING COVID-19 VACCINATION, BUT NOT TREATMENT, IS AN INDEPENDENT RISK FACTOR FOR BREAKTHROUGH SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IGIBD STUDY Macaluso, F.S. Principi, M. Facciotti, F. Contaldo, A. Todeschini, A. Saibeni, S. Bezzio, C. Castiglione, F. Nardone, O. Spagnuolo, R. Fantini, M. Riguccio, G. Conforti, F. Caprioli, F. Vigano, C. Felice, C. Fiorino, G. Correale, C. Bodini, G. Milla, M. Scardino, G. Vernero, M. Desideri, F. Bossa, F. Guerra, M. Ventimiglia, M. Mannino, M. Rizzo, G. Orlando, A. Dig Liver Dis Oral Communications Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. 2023-03 2023-03-23 /pmc/articles/PMC10033231/ http://dx.doi.org/10.1016/S1590-8658(23)00321-3 Text en Copyright © 2023 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Oral Communications Macaluso, F.S. Principi, M. Facciotti, F. Contaldo, A. Todeschini, A. Saibeni, S. Bezzio, C. Castiglione, F. Nardone, O. Spagnuolo, R. Fantini, M. Riguccio, G. Conforti, F. Caprioli, F. Vigano, C. Felice, C. Fiorino, G. Correale, C. Bodini, G. Milla, M. Scardino, G. Vernero, M. Desideri, F. Bossa, F. Guerra, M. Ventimiglia, M. Mannino, M. Rizzo, G. Orlando, A. OC.14.2 LACK OF SEROCONVERSION FOLLOWING COVID-19 VACCINATION, BUT NOT TREATMENT, IS AN INDEPENDENT RISK FACTOR FOR BREAKTHROUGH SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IGIBD STUDY |
| title | OC.14.2 LACK OF SEROCONVERSION FOLLOWING COVID-19 VACCINATION, BUT NOT TREATMENT, IS AN INDEPENDENT RISK FACTOR FOR BREAKTHROUGH SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IGIBD STUDY |
| title_full | OC.14.2 LACK OF SEROCONVERSION FOLLOWING COVID-19 VACCINATION, BUT NOT TREATMENT, IS AN INDEPENDENT RISK FACTOR FOR BREAKTHROUGH SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IGIBD STUDY |
| title_fullStr | OC.14.2 LACK OF SEROCONVERSION FOLLOWING COVID-19 VACCINATION, BUT NOT TREATMENT, IS AN INDEPENDENT RISK FACTOR FOR BREAKTHROUGH SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IGIBD STUDY |
| title_full_unstemmed | OC.14.2 LACK OF SEROCONVERSION FOLLOWING COVID-19 VACCINATION, BUT NOT TREATMENT, IS AN INDEPENDENT RISK FACTOR FOR BREAKTHROUGH SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IGIBD STUDY |
| title_short | OC.14.2 LACK OF SEROCONVERSION FOLLOWING COVID-19 VACCINATION, BUT NOT TREATMENT, IS AN INDEPENDENT RISK FACTOR FOR BREAKTHROUGH SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IGIBD STUDY |
| title_sort | oc.14.2 lack of seroconversion following covid-19 vaccination, but not treatment, is an independent risk factor for breakthrough sars-cov-2 infection in patients with inflammatory bowel disease: data from escape - an igibd study |
| topic | Oral Communications |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033231/ http://dx.doi.org/10.1016/S1590-8658(23)00321-3 |
| work_keys_str_mv | AT macalusofs oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT principim oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT facciottif oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT contaldoa oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT todeschinia oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT saibenis oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT bezzioc oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT castiglionef oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT nardoneo oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT spagnuolor oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT fantinim oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT rigucciog oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT confortif oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT capriolif oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT viganoc oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT felicec oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT fiorinog oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT correalec oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT bodinig oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT millam oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT scardinog oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT vernerom oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT desiderif oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT bossaf oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT guerram oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT ventimigliam oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT manninom oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT rizzog oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy AT orlandoa oc142lackofseroconversionfollowingcovid19vaccinationbutnottreatmentisanindependentriskfactorforbreakthroughsarscov2infectioninpatientswithinflammatoryboweldiseasedatafromescapeanigibdstudy |